Nanotechnology Now - Press Release: Cancer Therapeutics Retains The Cervelle Group to Spearhead Its Communication Program

Home > Press > Cancer Therapeutics Retains The Cervelle Group to Spearhead Its Communication Program

Abstract:
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments, announced today the company has retained The Cervelle Group, a nationally known investor relations and public relations firm to manage the company's communications program with shareholders and the media. Cancer Therapeutics is compensating The Cervelle Group 75,000 shares of restricted common stock for the three (3) months of service.

Cancer Therapeutics Retains The Cervelle Group to Spearhead Its Communication Program

Salt Lake City, UT | Posted on May 6th, 2009

The Cervelle Group (www.thecervellegroup.com), based in Orlando, FL, will focus on communicating with shareholders, prospective investors and the media concerning Cancer Therapeutics. They will also assist with the dispensing of information on the Company as well as its growth strategy and broadening the Company's visibility.

"Medicine and treatments for a variety of diseases and ailments are continuing to advance at a record pace, we believe the idea of what Cancer Therapeutics is based on is not only a valid story but is a real company with tremendous potential," said Rob M. Karbowsky, President of the Cervelle Group LLC. "Cervelle specializes in working with undiscovered companies who have solid management, a great story to tell and a significant upside for revenue generation -- CTHP has these characteristics."

####

About Cancer Therapeutics, Inc.
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in its pipeline.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.

For more information, please click here

Contacts:
Investor Relations
David Donlin
Cervelle Group
Phone: 407-614-5959 ext. 223

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: